Harnessing computational biology and AI/ML methodologies to develop transformative medicines, beginning with Parkinson’s disease
Our mission
Our mission is to transform the treatment of complex diseases utilizing novel discoveries empowered by artificial intelligence and omics data. We develop advanced deep learning algorithms to analyze complex biological data, revealing novel therapeutic targets and drug candidates.
Enabled by our proprietary platform, we have decoded molecular mechanisms and identified therapeutic opportunities to restore brain health in Parkinson’s disease.
At Sinopia, we unite data science innovation, deep biological insight, and a commitment to patients to accelerate the discovery of breakthrough treatments that change the course of Parkinson’s disease and improve lives.
Executive Leadership
Iman Famili, Ph.D.
President and CEO
Board of Directors
Arthur T. Suckow, Ph.D.
Executive Chair
Scientific Advisory Board
Aarash Bordbar, Ph.D.
CTO
Kalpana Merchant, Ph.D.
Abhay Joshi, Ph.D. MBA
Tanya Simuni, M.D.
Acting CMO
Bernhard O. Palsson, Ph.D.
David M. Weiner, M.D.